DexCom, Inc. (NASDAQ:DXCM) Holdings Decreased by Sterling Capital Management LLC

Sterling Capital Management LLC decreased its holdings in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 6.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 266,632 shares of the medical device company's stock after selling 18,528 shares during the quarter. Sterling Capital Management LLC owned approximately 0.07% of DexCom worth $20,736,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of DXCM. Versant Capital Management Inc acquired a new position in shares of DexCom in the 4th quarter valued at $25,000. Private Trust Co. NA boosted its holdings in DexCom by 266.3% in the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock valued at $26,000 after acquiring an additional 245 shares during the last quarter. TD Private Client Wealth LLC grew its position in DexCom by 62.8% during the fourth quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock valued at $34,000 after acquiring an additional 167 shares during the period. Larson Financial Group LLC raised its holdings in shares of DexCom by 40.5% in the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock worth $37,000 after purchasing an additional 137 shares during the period. Finally, Heck Capital Advisors LLC acquired a new position in shares of DexCom in the 4th quarter valued at about $38,000. Institutional investors and hedge funds own 97.75% of the company's stock.

Insider Buying and Selling at DexCom

In related news, CEO Kevin R. Sayer sold 32,498 shares of the stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total value of $2,287,209.24. Following the completion of the transaction, the chief executive officer now directly owns 372,029 shares of the company's stock, valued at $26,183,401.02. This represents a 8.03 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Michael Jon Brown sold 13,000 shares of DexCom stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total value of $914,940.00. Following the sale, the executive vice president now directly owns 105,602 shares in the company, valued at $7,432,268.76. The trade was a 10.96 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 105,009 shares of company stock worth $8,044,178. 0.30% of the stock is owned by insiders.

Remove Ads

Analysts Set New Price Targets

DXCM has been the topic of several research reports. Wells Fargo & Company restated an "overweight" rating on shares of DexCom in a report on Saturday, March 8th. Baird R W upgraded DexCom from a "hold" rating to a "strong-buy" rating in a report on Thursday, January 16th. Citigroup upped their target price on DexCom from $101.00 to $104.00 and gave the stock a "buy" rating in a research report on Tuesday, March 4th. Cfra Research raised shares of DexCom to a "hold" rating in a research report on Friday, March 21st. Finally, Robert W. Baird raised shares of DexCom from a "neutral" rating to an "outperform" rating and raised their price target for the company from $86.00 to $104.00 in a report on Thursday, January 16th. Five investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat.com, DexCom has an average rating of "Moderate Buy" and an average target price of $99.00.

DexCom Stock Performance

Shares of NASDAQ:DXCM traded up $1.84 during trading on Tuesday, reaching $69.23. 4,613,300 shares of the company's stock traded hands, compared to its average volume of 4,176,273. The stock has a market capitalization of $27.15 billion, a P/E ratio of 48.41, a price-to-earnings-growth ratio of 2.30 and a beta of 1.50. DexCom, Inc. has a 12 month low of $57.52 and a 12 month high of $139.24. The company has a 50 day moving average of $76.49 and a 200-day moving average of $76.68. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its earnings results on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. On average, equities analysts expect that DexCom, Inc. will post 2.03 EPS for the current year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.